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Background: The purpose of this study was to determine the yield of stereotactic core breast 
biopsy and its cost-saving potential.
Methods: This observational study was conducted at the Department of Radiology at Aga Khan 
Hospital in Karachi. All female patients (n = 84) undergoing stereotactic core breast biopsy 
under mammographic guidance from January 2005 to May 2010 were included.   Stereotactic 
core biopsy was performed on a dedicated mammography unit employing a 14-gauge needle 
with an automated biopsy device. Ten patients with incomplete medical records were excluded. 
All breast biopsy results were either compared with surgical findings in cases of malignant 
histopathological findings or with follow-up needle localization in case of benign core biopsy 
findings.
Results: Fifteen of our 74 patients had malignant findings on stereotactic biopsy, confirmed on 
histopathology of the final surgical mastectomy specimen. The remaining 59 patients had benign 
results on histopathology; five patients had needle localization of the same area due to either 
suspicious mammographic findings or clinical suspicion of malignancy. All were proven to be 
histopathologically benign on open surgical biopsy. Fifty-four patients with benign results had 
follow-up mammograms, and the follow-up period was 18 months to 5 years. The sensitivity 
and specificity was 100%. The cost saving per patient was US$253.
Conclusion: Stereotactic core breast biopsy is a safe and cost-effective method for determining 
the nature of suspicious mammographic findings.
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Introduction
Breast cancer is the most common cause of morbidity and mortality among women 
worldwide.1 More than half of patients with breast cancer reside in developing 
  countries, where resources to fight the disease are limited.2 Most women suspected 
of having breast cancer are referred for breast biopsy to determine if the lesion seen 
on imaging is benign or malignant and whether further work-up and management is 
warranted. Most women undergoing breast biopsy have benign lesions and do not 
require further treatment. Recently published data for screening studies showed that 
2616 open biopsies were performed in the UK in 2008–2009 and that 69% of these 
were benign and 31% were malignant. The malignant biopsy rate has shown a decline 
from 2.04 per 1000 women in 1996–1997 to 0.40 per 1000 women in 2008–2009, and 
that the nonoperative diagnosis rate for cancers has increased from 63% to 95%.3
Breast biopsies may be performed by open surgery (incisional or excisional biopsy) 
or by minimally invasive core needle biopsy. Core needle biopsy involves removing International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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small cores of breast tissue obtained by a shallow core 
needle inserted through the skin. Core needle biopsy is less 
expensive, has fewer complications and a shorter recovery 
time, and incurs less psychological trauma. According to a 
systematic review, stereotactic-guided and ultrasonography-
guided core needle biopsy procedures seem to be almost 
as accurate as open surgical biopsies, and have a lower 
  complication rate.4
Stereotactic breast biopsy using a 14-gauge needle is a 
reliable method of biopsy for nonpalpable breast lesions.5 
The data suggest that 2%–4% of women undergoing 
screening mammography are referred for biopsy of a mam-
mographic abnormality.6 The majority of these patients 
have benign lesions. The effort and cost involved in further 
evaluation of these abnormalities is huge, and most of this 
is incurred by surgical biopsies. Stereotactic breast biopsy is 
a less expensive and less invasive method of breast biopsy 
for evaluating mammographically detected suspicious 
breast lesions.
We conducted this study to determine the yield of 
stereotactic core needle biopsy for evaluation of mammo-
graphically detected nonpalpable lesions, and its effect on 
cost saving for the patient.
Methods
This descriptive study was conducted in the Department of 
Radiology at the Aga Khan University Hospital in   Karachi 
from January 2005 to May 2010. All patients (n = 84) 
undergoing stereotactic breast biopsy in the department 
were included. All prebiopsy mammograms were reviewed 
independently by two consultant radiologists. The 
mammographic findings were categorized according to the 
Breast Imaging Reporting And Data System (BI-RADS®)
assessment criteria. The biopsy was performed on a 
Mammomat Nova 3000 (Siemens AG, Berlin, Germany)
using an Opdima stereotactic biopsy device. A 14-gauge 
needle with an automated gun was used. On average, 
5–6 cores were taken. The specimens removed were 
radiographed to confirm that the sample contained the 
targeted suspicious microcalcifications or parenchymal 
density. Ten patients with incomplete medical records 
were excluded. The age of the patient, indication for 
mammography, histopathological outcome, and further 
management were recorded from patients’ personal files. 
Concordance between the mammographic abnormality 
and histopathological results was determined using Kappa 
statistics. A P value ,0.05 was considered statistically 
significant.
The yield was determined by calculating the sensitivity 
and specificity of stereotactic core biopsy. The cost 
  comparison was done by calculating the difference between 
the charges for stereotactic biopsy and open surgical biopsy 
per patient.
Results
Eighty-four women underwent stereotactic core biopsy dur-
ing the study period. Their mean age was 57 ± 1.3 years. 
Of these, ten had incomplete medical records or follow-up 
and were excluded. Of the remaining 74 women, prebiopsy 
mammograms were categorized as BI-RADS II in 25 cases, 
BI-RADS III in 16 cases, BI-RADS IV in 27 cases, and BI-
RADS V in six cases. The biopsy was performed in patients 
with BI-RADS category II mammograms either because of 
strong family history or a history of malignancy in the contral-
ateral breast in order to decide on an appropriate management 
plan. Similarly, in mammograms reported as BI-RADS III, 
a biopsy was performed because the clinician did not want 
to wait for 6 months to obtain a follow-up mammogram, to 
alleviate patient anxiety, or if the clinician was concerned that 
the patient would not attend the follow-up mammography. 
Biopsy was performed in 23 patients to evaluate a suspicious 
parenchymal density or nodule and in the rest for suspicious 
microcalcifications seen on mammography. In a few patients, 
a mass was clinically palpable, but the clinician opted for 
image-guided biopsy as a means to target microcalcifications 
in the mass. Among the patients who underwent biopsy, 15 had 
malignant findings confirmed on histopathology of the final 
surgical mastectomy specimen. The remaining 59 patients 
had benign results on histopathology; five of these patients 
had needle localization in the same area due to either suspi-
cious mammographic findings or strong clinical suspicion of 
malignancy. All were proven histopathologically to be benign 
on open surgical biopsy. Fifty-four patients with benign results 
on histopathology were also followed up with mammograms. 
The follow-up period was 18 months to 5 years, and confirmed 
benign findings. The sensitivity and specificity was 100%. 
Excellent agreement was noted between mammographic 
abnormality and histopathological results with a Kappa value 
of 8 (P = 0.000). The cost of stereotactic core biopsy at our 
institution is US$100, whereas open   surgical biopsy after 
needle localization costs US$353. This represents an obvious 
cost saving of US$253 per patient.
Discussion
Pakistan has a higher burden of breast cancer than other 
Asian countries.7,8 Image-guided breast biopsy techniques International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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were developed to overcome the diagnostic problem 
of increasing numbers of suspicious lesions detected 
at mammography.7 Stereotactic breast biopsy using a 
14-gauge needle is an accurate method of tissue sampling 
for nonpalpable breast lesions, and was used for the first 
time in Sweden in 1974 for fine needle aspiration cytology.5 
Improvement in techniques over the last 30 years have 
allowed this method to be used to assess both palpable 
and nonpalpable lesions of the breast in both screening and 
symptomatic settings.9
According to most published reports, the targets for 
core biopsy are all types of nonpalpable mammographic 
abnormalities, including a mass, calcifications, or a   calcified 
mass.10–12 The reported concordance for surgical and 
stereotactic biopsy is 87%–96%.10
Our results show that 80% of all lesions biopsied were 
benign, which is comparable with a study conducted by 
Jackman et al.13 Recently published screening data from the 
UK show that 2616 open surgical biopsies were performed 
in 2008–2009, of which 69% were benign and 31% were 
malignant.3
Biopsy results strongly influence the algorithm for 
evaluation of suspicious lesions. The biopsy method must 
be minimally invasive, accurate, and cost-effective. The 
cost of stereotactic core biopsy at our institution is US$100 
whereas the cost of open surgical biopsy after needle local-
ization is US$353. This represents an obvious cost saving 
of US$253 per patient.
Open surgical biopsy requires a 1-day hospital admission, 
and is associated with more anxiety on the part of the patient 
about undergoing a procedure in an operating room. It is also 
associated with more breast scarring. In contrast, stereotactic 
breast biopsy does not require hospital admission and the 
entire procedure is completed in 1 hour, it is associated 
with no scarring clinically or radiologically, and patients 
can resume their daily activities immediately after the 
procedure.
Our study showed a sensitivity of 100%, which is 
  comparable with that in a study conducted by Peters et al.14 
In this study, all patients with benign findings on stereotactic 
biopsy underwent surveillance mammography which is 
routine clinical practice. No breast malignancy was missed 
on surveillance mammography after 2 years of follow-up 
mammography. However, the COBRA (COre Biopsy after 
RAdiological localization)15 study reported a sensitivity 
of 97%. In COBRA, all lesions, whether benign or malig-
nant on stereotactic core needle biopsy, underwent open 
surgical biopsy.
Our specificity was 100% which is similar to the 99% 
specificity reported by the COBRA study, in which 973 
patients under went stereotactic core needle biopsy followed 
by open surgical biopsy if the results of stereotactic core 
needle biopsy were benign, and therapeutic surgery if the 
results of stereotactic core needle biopsy were malignant. 
In our study, only five patients underwent open surgical 
biopsy if the results were benign, and the rest of the patients 
were followed up by surveillance mammography over a 
follow-up period of 18 months to 5 years.
There were a few limitations to our study. A small sample 
size might have resulted in 100% sensitivity and specificity; 
all patients with benign results on stereotactically guided 
core needle biopsy did not undergo open surgical biopsy, and 
were followed up by surveillance mammography, although 
the follow-up period ranged from 18 months to 5 years.
Conclusion
Stereotactic core breast biopsy is a safe and cost-effective 
method for determining the nature of suspicious finding 
on mammograms. In patients with benign findings on 
stereotactically guided core needle biopsy, surgical excision 
is not warranted, but studies with larger numbers of patients 
are needed to generalize this recommendation.
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